Background

Cardiovascular disease (CVD) includes conditions such as coronary heart disease, stroke, heart failure, arrhythmia, heart valve disease, congenital heart disease, and hypertension. The American Heart Association has estimated that CVD affects 83.6 million individuals in the United States, contributes to 32.3 percent of deaths, and is a leading cause of disability.1 Atherosclerosis (hardening of arteries caused by plaque deposition) causes coronary heart disease (CHD), cerebrovascular disease, and peripheral artery disease. The American Heart Association estimates that atherosclerotic CVD affects 15.4 million Americans.1 CHD, which includes coronary artery disease, myocardial infarction (MI), unstable angina, and heart failure, is a leading cause of death for both men and women in the United States.2 It is estimated that by 2030, the prevalence of CHD will rise by 16.6 percent and result in more than $106 billion in direct health care costs.3

Abnormal lipoprotein metabolism, especially increased concentrations of apo B-100–containing low-density lipoprotein (LDL-c), predisposes individuals to atherosclerosis. Due to the consistent and robust association of higher LDL-c levels with atherosclerotic CVD across experimental and epidemiologic studies,4,5 therapeutic strategies to decrease risk have focused on LDL-c reduction as a primary goal. In contrast to LDL-c, high-density lipoprotein (HDL-c) has a protective role against atherosclerotic

Effective Health Care Program

The Effective Health Care Program was initiated in 2005 to provide valid evidence about the comparative effectiveness of different medical interventions. The object is to help consumers, health care providers, and others in making informed choices among treatment alternatives. Through its Comparative Effectiveness Reviews, the program supports systematic appraisals of existing scientific evidence regarding treatments for high-priority health conditions. It also promotes and generates new scientific evidence by identifying gaps in existing scientific evidence and supporting new research. The program puts special emphasis on translating findings into a variety of useful formats for different stakeholders, including consumers.

The full report and this summary are available at www.effectivehealthcare.ahrq.gov/reports/final.cfm.
Questions remain as to how best to modify lipid levels with the goal of preventing CHD. The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are the most widely prescribed lipid-lowering agents and are often used as monotherapy. However, some patients do not reach their treatment goals on statin monotherapy or are troubled by side effects, prompting interest in combination therapy as a way to improve lipid levels without having to increase statin dosage or as a way to reduce side effects. Statins can be combined with an additional lipid-modifying medication such as a bile acid sequestrant, cholesterol absorption inhibitor, fibric acid, nicotinic acid, or omega-3 fatty acid. There are potential benefits to treating with multiple agents, as the different mechanisms of action of the other lipid-modifying agents may produce benefits unlikely to be achieved with a statin alone. For example, a fibrate or niacin in combination with a statin may increase HDL-c and decrease triglycerides above what is achieved with statin treatment alone. Combination therapy could potentially result in fewer statin-related side effects (e.g., myalgias and elevated liver transaminases), as lower doses of statin could be used. Conversely, a combination of agents could result in an increase in side effects, as patients may experience the side effects common to both drugs.

In 2009, the Agency for Healthcare Research and Quality released an evidence report comparing combinations of these lipid-modifying agents to statin intensification. However, the authors found insufficient evidence to determine whether combination therapy held benefit over monotherapy. To provide additional information for clinicians treating patients with moderate or high CHD risk, this update reviews the most recent evidence.

Two contextual factors need to be kept in mind while considering the evidence comparing statin intensification to combination therapy. First, guideline recommendations about intensifying statin therapy or adding an additional nonstatin agent to achieve a specific lipid target level have recently changed. The National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III provided guidelines on both when to initiate lipid-lowering therapy based on LDL-c level and CHD risk factors and recommended LDL-c targets for optimal CHD risk reduction. However, the new guidelines for treatment of cholesterol to reduce atherosclerotic CVD, released in November 2013, represent a major change from the ATP III guidelines. No specific LDL-c targets (e.g., LDL-c ≤70 mg/dL) were presented in the new guidelines due to the lack of evidence from randomized controlled trials supporting specific targets. Rather, four “statin benefit groups” were identified: individuals with clinical atherosclerotic CVD, individuals with LDL-c ≥190 mg/dL, people with diabetes aged 40–75, and individuals aged 40–75 with a ≥7.5-percent 10-year atherosclerotic CVD risk. For individuals within these groups, there are recommendations for treatment with moderate- or high-potency statins. The expected response to a moderate-potency statin is an LDL-c reduction of 30 to 50 percent, while the expected response to a high-potency statin is an LDL-c reduction of ≥50 percent. For individuals who do not have the expected response, adherence is assessed. Then the guidelines recommend considering intensification of statin therapy if the patient is not at maximum dose or the addition of a nonstatin agent with proven efficacy in reducing CVD events.

Second, several large trials, such as ENHANCE (The Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression), AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL Cholesterol/High Triglyceride and Impact on Global Health Outcomes), and ACCORD (Action to Control Cardiovascular Risk in Diabetes)-Lipid, have compared statin monotherapy to combination therapy with the same statin dose plus another lipid-lowering drug. These trials have demonstrated that “add-on” combination therapy can lead to superior lipid outcomes but fails to reduce atherosclerosis or lead to decreased rates of cardiovascular death, MI, revascularization, or stroke. This evidence calls into question previous assumptions that lowering LDL-c or raising HDL-c are always reliable predictors of improved clinical outcomes, as well as increasing the importance of patient-centered clinical outcomes for evaluating the effectiveness of lipid-modifying therapies.

Scope and Key Questions

We aimed to assess the effectiveness, safety, and tolerability of the combination of statin and other lipid-modifying medication compared to intensification of statin monotherapy. Our scope was limited to comparing the combination of statin with other lipid-modifying medication to intensification of statin monotherapy. We did not examine the separate but related question of whether adding another lipid-modifying agent to the same potency statin therapy will improve clinical outcomes (add-on combination therapy). Therefore, a
number of high-profile studies that evaluated add-on combination therapy, including ACCORD, AIM-HIGH, HSP-2 THRIVE (Heart Protection Study 2 Treatment of HDL to Reduce the Incidence of Vascular Events), and ENHANCE, are not included in this review. We did not expand our update to evaluate add-on combination therapy for two reasons: (1) the upcoming release of the IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International) trial results, which will be critical in characterizing the effect of add-on combination therapy with ezetimibe + statin on clinical outcomes, thereby making a review at this time premature; and (2) resource constraints. Furthermore, we did not include nonstatin monotherapy as a comparison group, given that statins are the first-line treatment for dyslipidemia and the focus of this update is on populations that can tolerate statins at some dose. We aimed to answer the questions below by reviewing trials of adults that compared a higher potency of statin monotherapy to a lower potency statin in combination with another agent (bile acid sequestrant, ezetimibe, fibrate, niacin, or omega-3 fatty acid).

The specific Key Questions (KQs) are:

KQ 1: For patients who require intensive lipid-modifying therapy, what are the comparative long-term benefits and rates of serious adverse events of coadministration of different lipid-modifying agents (i.e., a statin plus another lipid-modifying agent) compared with higher dose statin monotherapy?

KQ 2: Do these regimens differ in reaching LDL targets (or other surrogate markers), short-term side effects, tolerability, and/or adherence?

KQ 3: Compared with higher dose statins and with one another, do combination regimens differ in benefits and harms within subgroups of patients?

The analytic framework for our review is shown in Figure A.

Methods

Search Strategy, Study Selection, and Data Abstraction

We searched the following databases for primary studies: MEDLINE®, Embase®, and the Cochrane Central Register of Controlled Trials (CENTRAL) from May 2008 through July 2013. We also reviewed relevant review articles. In addition, we requested and reviewed Scientific Information Packets provided by the pharmaceutical manufacturers. Abstract and full-text screening was performed by two independent reviewers using prespecified eligibility criteria (Table A). All articles included in the prior review were reviewed during the full-text screen. Conflicts were resolved by consensus adjudication.

Data abstraction was conducted with a senior reviewer (faculty-level project investigator) abstracting data from articles while having access to the first reviewer’s data abstraction. Differences in opinion were resolved through consensus adjudication and, for difficult cases, during team meetings.

Risk-of-Bias Assessment

Risk of bias was assessed independently by two reviewers using the Cochrane Collaboration’s tool. For studies included from the prior review, we used the quality assessments from that report, which used the Jadad Score.

Data Synthesis

We compared lower potency statins in combination therapy with higher potency statin monotherapy, which enabled us to synthesize data across statin type and statin dose. We used specific criteria to determine statin potency (Table B).

We calculated and displayed the mean differences with 95-percent confidence intervals for the individual studies grouped by combination therapy agent, statin potency, and population for all comparisons. We considered meta-analysis where there were three or more similar studies. We report qualitative synthesis of data for most outcomes because of the lack of outcomes meeting our criteria for meta-analysis and significant heterogeneity detected when meta-analyses were conducted ($I^2 >50\%$).

Strength of the Body of Evidence

We graded the quantity, quality, and consistency of the evidence for the following outcomes: mortality, acute coronary events, revascularization procedures, serious adverse events, LDL-c, and HDL-c. We used an evidence grading scheme recommended by the “Methods Guide for Effectiveness and Comparative Effectiveness Reviews.”

We created evidence grades for each comparison and outcome by combination agent, statin potency, and population. We used four domains to yield a final evidence grade: risk of bias, consistency, directness and precision. The final strength-of-evidence (SOE) grades were: (1) “high” grade (indicating high confidence that the evidence reflects the true effect and further research is
Patients at moderate or greater risk of cardiovascular disease

- Elderly
- Females
- Race/ethnicity
- DM
- Preexisting CVD

Subgroups

Dual-agent therapy vs. intensification of statin therapy

- LDL-c
- HDL-c
- Total cholesterol: HDL-c ratio
- Atherosclerosis
- Triglyceride (DM only)
- Non-HDL-c (DM only)

KQ1

KQ2

Adherence
- Adverse events
- Cancer
- Elevated liver transaminases
- Musculoskeletal adverse events
- Diabetes mellitus
- Acute kidney injury

KQ3

- Mortality
- Coronary heart disease
- Cerebrovascular disease
- Revascularization procedure
- Severe adverse effects

Figure A. Analytic framework for comparative effectiveness of lipid-modifying agents

CVD = cardiovascular disease; DM = diabetes mellitus; HDL-c = high-density lipoprotein; KQ = Key Question; LDL-c = low-density lipoprotein
### Table A. Study inclusion and exclusion criteria

| **Population and Condition of Interest** | Included adults with moderate (10-year CHD risk 10-20% or LDL-c ≥160 mg/dL) or high (10-year CHD risk ≥20% or LDL-c ≥190 mg/dL) cardiovascular disease risk.  
*Excluded* studies if they included only adults with low cardiovascular disease risk (CHD risk <10% or LDL-c <160 mg/dL).  
*Excluded* studies that included only patients with homozygous FH. |
| **Interventions and Approaches** | Studies must have evaluated a combination regimen of interest.  
Included studies of bile acid sequestrants + statin.  
Included studies of ezetimibe + statin.  
Included studies of fibrates + statin.  
Included studies of niacin + statin.  
Included studies of omega-3 fatty acids + statin.  
*Excluded* studies of lifestyle modifications.  
*Excluded* studies of drugs approved only for the treatment of homozygous FH.  
*Excluded* studies of drugs not approved by the FDA or investigational drugs.  
*Excluded* studies of prepackaged medications that contained non–lipid-lowering medications. |
| **Comparisons of Interest** | Included comparisons with higher potency statin monotherapy.  
*Excluded* studies if a study statin monotherapy was of the same or lower potency than combination arm.  
*Excluded* studies if there was no comparison or only placebo comparison. |
| **Outcomes and Timing** | Included clinical outcomes—mortality, cardiovascular events, cerebrovascular events, and revascularization procedures at any time point.  
Included surrogate outcomes—LDL-c, HDL-c, TC:HDL-c ratio, NCEP ATP III LDL-c target attainment, and measures of atherosclerosis at any time point. Included triglycerides and non–HDL-c in diabetes subgroup.  
Included adherence and harms outcomes—adherence, serious adverse events (as reported by investigators), withdrawal due to adverse events, cancer, elevated liver transaminases, adverse musculoskeletal events, diabetes mellitus, and acute kidney injury at any time point. |
| **Type of Study** | Included studies with any sample size that met all other criteria.  
Included studies from the prior report that met all other criteria.  
Included randomized controlled trials  
Included nonrandomized extension of clinical trial over 24 weeks duration (clinical outcomes, SAE, and harms only).  
Included FDA reports (SAE and harms only).  
*Excluded* studies with other observational designs.  
*Excluded* studies with no original data (reviews, editorials, comments, letters, modeling-only studies).  
*Excluded* studies published only as abstracts.  
*Excluded* qualitative studies.  
*Excluded* crossover trials with fewer than 4 weeks washout and/or lacking paired observation, within-person differences, or precrossover data.  
*Excluded* non–English-language publications. |

CHD = coronary heart disease; FDA = U.S. Food and Drug Administration; FH = familial hypercholesterolemia; HDL-c = high-density lipoprotein; LDL-c = low-density lipoprotein; NCEP ATP III = National Cholesterol Education Program Adult Treatment Panel III; SAE = serious adverse event; TC = total cholesterol.

very unlikely to change our confidence in the estimate of the effect); (2) “moderate” grade (indicating moderate confidence that the evidence reflects the true effect and may change the estimate); (3) “low” grade (indicating low confidence that the evidence reflects the true effect and is likely to change the estimate); and (4) “insufficient” grade (no evidence identified). A comparison-outcome pair with high SOE was one with low risk of bias, directness, consistency, and precision. Moderate SOE indicated that a high risk of bias was noted or that two of the following were observed: a moderate risk of bias, inconsistency, indirectness, or imprecision. Low SOE indicated a high risk of bias and two or more of the following or a moderate risk of bias and three of the following: inconsistency, indirectness, and imprecision.

Investigators writing each section completed the SOE grading, which was then reviewed by the team.

Applicability

We describe the applicability of studies in terms of the degree to which the study population, interventions, outcomes, and settings were relevant to individuals at high CHD risk requiring aggressive lipid-modifying therapy and features that may affect the effectiveness of the intervention.

Results

Results of Literature Searches

Figure B summarizes the search results. The literature search identified 4,293 unique citations. During the title and abstract screening we excluded 3,396 citations; during the article screening we excluded 380 citations (see Appendix D of the full report). Fifty-five studies, reported in 59 articles, were included. All trials were randomized controlled trials.

Overview of Included Trials by Potency and Agent

The SOE was variable across comparisons evaluating the effectiveness and safety of combination therapy versus intensification of statin monotherapy. Evidence for all the clinical outcomes of mortality, acute coronary events, and revascularization procedures was graded as insufficient across all potency comparisons for all combination therapy regimens.

Seven comparisons had moderate SOE for LDL-c and HDL-c outcomes. However, all other comparisons and outcomes had low or insufficient evidence. The interventions and approaches that effectively lowered LDL-c or raised HDL-c are described by combination therapy regimen below. The SOE for the body of evidence is provided in Table C for general populations and Table D for subgroups.

Table B. Different dosing of specific statins based on potency to reduce LDL-c

<table>
<thead>
<tr>
<th>Potency</th>
<th>Atorvastatin (mg/day)</th>
<th>Fluvastatin (mg/day)</th>
<th>Fluvastatin XL (mg/day)</th>
<th>Lovastatin (mg/day)</th>
<th>Pitavastatin (mg/day)</th>
<th>Pravastatin (mg/day)</th>
<th>Rosuvastatin (mg/day)</th>
<th>Simvastatin (mg/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low potency (&lt;30% LDL-c reduction)</td>
<td>5</td>
<td>20 and/or 40</td>
<td>--</td>
<td>5 and/or 10 and/or 20</td>
<td>1</td>
<td>10 and/or 20 and/or 40</td>
<td>--</td>
<td>10</td>
</tr>
<tr>
<td>Mid potency (30-40% LDL-c reduction)</td>
<td>10</td>
<td>80</td>
<td>80</td>
<td>40 and/or 80</td>
<td>2 and/or 4</td>
<td>80</td>
<td>2.5&lt;sup&gt;a&lt;/sup&gt;</td>
<td>20</td>
</tr>
<tr>
<td>High potency (&gt;40% LDL-c reduction)</td>
<td>20 and/or 40 and/or 80</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>5 and/or 10 and/or 20 and/or 40</td>
<td>40 and/or 80&lt;sup&gt;b&lt;/sup&gt;</td>
<td>40</td>
</tr>
</tbody>
</table>

LDL-c = low-density lipoprotein

<sup>a</sup>Dose not included in this review; information obtained from “FDA Advisory Committee Meeting Briefing Document NDA 21-366 for the use of CRESTOR” (www.fda.gov/ohrms/dockets/ac/03/briefing/3968b1_02_a-fda-clinical%20review.pdf).

<sup>b</sup>Studies that used simvastatin 80 mg in statin-naïve patients were excluded.
Figure B. Summary of search (number of articles)

Electronic Databases
MEDLINE® (2,925)
EMBASE® (899)
Cochrane (327)
SIP (82)

Retrieved 4,293

Duplicates 551

Title-Abstract Screening 3,742

Excluded 3,396

Full-Text Screening 439

Excluded 380

Included Articles/Studies 59/55

Reasons for Exclusion at Title-Abstract Screening Level
- Study published before 2008 = 0
- Not conducted in humans = 12
- No original data = 1,620
- Not in English and not able to determine eligibility = 141
- No full report (e.g., conference or meeting abstract) = 12
- Not an RCT or non-randomized that is extension of RCT that lasts >24 weeks = 302
- Drug is not available in the U.S./non-approved (e.g., investigational fibrate) = 122
- Not relevant to Key Questions = 2,275
- Other = 87

Reasons for Exclusion at Full-Text Screening Level
- Not conducted in humans = 0
- No original data = 71
- No full report (e.g., conference or meeting abstract) = 3
- Not in English and not able to determine eligibility = 6
- Study of children only = 1
- Only healthy subjects with low cardiovascular disease risk (CHD risk < 10 percent or LDL < 160 mg/dl) = 4
- Not an RCT or non-randomized that is extension of RCT that lasts > 24 weeks = 8
- Drug is not available in the U.S./non-approved (e.g., investigational fibrate) = 1
- Address inpatient only = 0
- Not relevant to Key Questions = 180
- Other (e.g., dose not different in monotherapy and combination regimens, no abstractable data) = 115

CHD = coronary heart disease; LDL = low-density lipoprotein; RCT = randomized controlled trial; SIP = Scientific Information Packet

*Total exceeds the number of citations in the exclusion box because citations could be excluded for more than one reason.

<table>
<thead>
<tr>
<th>Combination Agent</th>
<th>Potency Comparison (Combination Therapy vs. Monotherapy)</th>
<th>Clinical Events</th>
<th>Surrogate Markers</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Mortality</td>
<td>Acute Coronary Events</td>
</tr>
<tr>
<td>Bile Acid Sequestrant</td>
<td>Low-potency combination therapy vs. high-potency monotherapy</td>
<td>Insufficient</td>
<td>Insufficient</td>
</tr>
<tr>
<td></td>
<td>Mid-potency combination therapy vs. high-potency monotherapy</td>
<td>Insufficient</td>
<td>Insufficient</td>
</tr>
<tr>
<td></td>
<td>Low-potency combination therapy vs. mid-potency monotherapy</td>
<td>Insufficient</td>
<td>Insufficient</td>
</tr>
<tr>
<td>Ezetimibe</td>
<td>Low-potency combination therapy vs. high-potency monotherapy</td>
<td>Insufficient</td>
<td>Insufficient</td>
</tr>
<tr>
<td></td>
<td>Mid-potency combination therapy vs. high-potency monotherapy</td>
<td>Insufficient</td>
<td>Insufficient</td>
</tr>
<tr>
<td></td>
<td>Low-potency combination therapy vs. mid-potency monotherapy</td>
<td>Insufficient</td>
<td>Insufficient</td>
</tr>
<tr>
<td>Combination Agent</td>
<td>Potency Comparison (Combination Therapy vs. Monotherapy)</td>
<td>Clinical Events</td>
<td>Surrogate Markers</td>
</tr>
<tr>
<td>-------------------</td>
<td>---------------------------------------------------------</td>
<td>----------------</td>
<td>------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mortality</td>
<td>Acute Coronary Events</td>
</tr>
<tr>
<td><strong>Fibrates</strong></td>
<td>Low-potency combination therapy vs. high-potency monotherapy</td>
<td>Insufficient</td>
<td>Insufficient</td>
</tr>
<tr>
<td></td>
<td>Mid-potency combination therapy vs. high-potency monotherapy</td>
<td>Insufficient</td>
<td>Insufficient</td>
</tr>
<tr>
<td></td>
<td>Low-potency combination therapy vs. high-potency monotherapy</td>
<td>Insufficient</td>
<td>Insufficient</td>
</tr>
<tr>
<td><strong>Niacin</strong></td>
<td>Low-potency combination therapy vs. high-potency monotherapy</td>
<td>Insufficient</td>
<td>Insufficient</td>
</tr>
<tr>
<td></td>
<td>Mid-potency combination therapy vs. high-potency monotherapy</td>
<td>Insufficient</td>
<td>Insufficient</td>
</tr>
<tr>
<td></td>
<td>Low-potency combination therapy vs. mid-potency monotherapy</td>
<td>Insufficient</td>
<td>Insufficient</td>
</tr>
<tr>
<td><strong>Omega-3 Fatty Acid</strong></td>
<td>Low-potency combination therapy vs. high-potency monotherapy</td>
<td>Insufficient</td>
<td>Insufficient</td>
</tr>
<tr>
<td></td>
<td>Mid-potency combination therapy vs. high-potency monotherapy</td>
<td>Insufficient</td>
<td>Insufficient</td>
</tr>
<tr>
<td></td>
<td>Low-potency combination therapy vs. mid-potency monotherapy</td>
<td>Insufficient</td>
<td>Insufficient</td>
</tr>
</tbody>
</table>

HDL = high-density lipoprotein; LDL-c = low-density lipoprotein

**Note:** Comparisons for which there was evidence are shown in bold.
<table>
<thead>
<tr>
<th>Subgroup</th>
<th>Combination Agent</th>
<th>Potency Comparison (Combination Therapy vs. Monotherapy)</th>
<th>Clinical Events</th>
<th>Surrogate Markers</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Mortality</td>
<td>Acute Coronary Events</td>
</tr>
<tr>
<td>Preexisting CHD</td>
<td>Ezetimibe</td>
<td>Low-potency combination therapy vs. high-potency monotherapy</td>
<td>Insufficient</td>
<td>Insufficient</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mid-potency combination therapy vs. high-potency monotherapy</td>
<td>Insufficient</td>
<td>Insufficient</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Low-potency combination therapy vs. mid-potency monotherapy</td>
<td>Insufficient</td>
<td>Insufficient</td>
</tr>
<tr>
<td></td>
<td>Fibrates</td>
<td>Mid-potency combination therapy vs. high-potency monotherapy</td>
<td>Insufficient</td>
<td>Insufficient</td>
</tr>
<tr>
<td>Diabetes</td>
<td>Ezetimibe</td>
<td>Low-potency combination therapy vs. high-potency monotherapy</td>
<td>Insufficient</td>
<td>Insufficient</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mid-potency combination therapy vs. high-potency monotherapy</td>
<td>Insufficient</td>
<td>Insufficient</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Low-potency combination therapy vs. mid-potency monotherapy</td>
<td>Insufficient</td>
<td>Insufficient</td>
</tr>
<tr>
<td></td>
<td>Fibrates</td>
<td>Low-potency combination therapy vs. mid-potency monotherapy</td>
<td>Insufficient</td>
<td>Insufficient</td>
</tr>
</tbody>
</table>

CHD = coronary heart disease; HDL-c = high-density lipoprotein; LDL-c = low-density lipoprotein

Note: Comparisons for which there was evidence are shown in bold.
Combination Therapy Versus Intensification of Statin Monotherapy

Combination Therapy With Bile Acid Sequestrant and Statin

Six randomized trials (410 participants) were identified. Four trials compared low-potency statin in combination with a bile acid sequestrant to mid-potency statin monotherapy (288 participants). Low-potency statin in combination with a bile acid sequestrant lowers LDL-c up to 14 percent more than mid-potency statin monotherapy (SOE: moderate). There was insufficient evidence to evaluate LDL-c outcomes for other potency comparisons or to compare HDL-c outcomes at any statin potency.

We found insufficient evidence to compare combined lipid-modifying therapy with a bile acid sequestrant and statin to intensification of statin monotherapy on the rates of serious adverse events, regardless of statin potency. No study reported on the comparative effectiveness of bile acid sequestrant plus statin on benefits or harms as compared to intensification of statin monotherapy among subgroups.

Combination Therapy With Ezetimibe and Statin

Forty randomized trials (10,955 participants) were identified, which primarily reported on surrogate outcomes such as LDL-c and HDL-c. Thirteen trials compared low-potency statin in combination with ezetimibe to high-potency statin monotherapy in general populations. Among general populations, low-potency statin in combination with ezetimibe more effectively lowers LDL-c and raises HDL-c than high-potency statin monotherapy (SOE: low).

Eleven trials compared mid-potency statin in combination with ezetimibe to high-potency statin monotherapy in general populations. Mid-potency statin combined with ezetimibe more effectively lowers LDL-c and raises HDL-c than high-potency statin monotherapy among general populations (SOE: moderate and low, respectively).

Six trials compared low-potency statin in combination with ezetimibe to mid-potency statin monotherapy in general populations. Low-potency statin in combination with ezetimibe more effectively lowers LDL-c and raises HDL-c than mid-potency statin monotherapy (SOE: moderate and low, respectively).

Twelve trials among patients with preexisting CHD and four trials among patients with diabetes compared mid-potency statin in combination with ezetimibe to high-potency statin monotherapy. Mid-potency statin combined with ezetimibe more effectively lowers LDL-c than high-potency statin monotherapy among patients with CHD (SOE: moderate); however, there was no difference in HDL-c effects (SOE: low). Mid-potency statin combined with ezetimibe more effectively lowers LDL-c and raises HDL-c than high-potency statin monotherapy among patients with diabetes (SOE: moderate).

Combination Therapy With Fibrate and Statin

Four randomized trials (1,341 participants) were identified. Two trials compared mid-potency statin in combination with a fibrate to high-potency statin monotherapy (683 participants). There is insufficient evidence to compare the benefits of combined lipid-modifying therapy with a fibrate and statin to intensification of statin monotherapy on LDL-c, HDL-c, and serious adverse events, regardless of statin potency.

Combination Therapy With Niacin and Statin

Five randomized trials (612 participants) were identified. Three trials compared low-potency statin in combination with niacin to mid-potency statin monotherapy (247 participants). We found inconsistent effects on lowering LDL-c when comparing low-potency statin in combination with niacin to mid-potency statin monotherapy. However, low-potency statin in combination with niacin raised HDL-c 15 percent to 27 percent more than mid-potency statin monotherapy (SOE: moderate).

We found insufficient evidence to compare combined lipid-modifying therapy with niacin and statin to intensification of statin monotherapy on the rates of long-term clinical outcomes and serious adverse events, regardless of statin potency. No study reported on the effectiveness of niacin plus statin compared to intensification of statin monotherapy on benefits or harms among subgroups.

Combination Therapy With Omega-3 Fatty Acid and Statin

No trials were identified that compared combination therapy with omega-3 fatty acid and statin to intensification of statin monotherapy. There is insufficient evidence to compare the benefits of combined lipid-modifying therapy with an omega-3 fatty acid and statin to intensification of statin monotherapy on LDL-c, HDL-c, and serious adverse events, regardless of statin potency.
Discussion

Key Findings

The evidence suggests that some combination therapy regimens may confer benefits with respect to lowering LDL-c, including bile acid sequestrants (up to 14 percent greater LDL-c reduction) and ezetimibe (up to 21 percent greater LDL-c reduction). LDL-c is an important factor in the development of atherosclerotic cardiovascular disease, and higher levels of LDL-c have been associated with greater risk of this disease. However, there is insufficient evidence to address whether the LDL-c–lowering benefits achieved with these medications translate into decreased rates of atherosclerotic cardiovascular disease. Prior trials comparing combination regimens to statin monotherapy, such as ENHANCE, AIM-HIGH, and ACCORD-Lipid, have demonstrated that combination therapy can lead to superior lipid outcomes but fail to reduce clinical outcomes such as cardiovascular death, MI, revascularization, or stroke.

We also found that some combination therapy regimens may confer benefits with respect to raising HDL-c, including ezetimibe (up to 6 percent) and niacin (up to 27 percent). In particular, given that only one prior study has demonstrated the benefit of pharmacologically raising HDL-c with respect to prevention of CVD events, the potential long-term clinical benefits of these combination regimens with respect to their HDL-c effects are unclear.

The strength of evidence is provided for all observed comparisons in general populations in Table C and for subgroups in Table D. Most trials included in this report were of relatively short duration (<3 months). In this limited timeframe, investigators are unlikely to capture any changes in a chronic condition such as atherosclerotic cardiovascular disease, which typically develops and progresses over a number of years. Powering such studies is especially difficult, given that both arms are taking statins, which would reduce the baseline incidence of cardiovascular events. Therefore, currently it is not possible to draw conclusions about the clinical implications of the surrogate marker changes identified. However, until additional data are available, these results may help health care providers tailor lipid-modifying regimens based on individual patient needs and concerns for adverse events.

Applicability

Many trials that met our inclusion criteria were implemented in patients with hyperlipidemia, and most were designed to evaluate effects on lipid measures and short-term harms. The results of most trials generalize to patients with hyperlipidemia uncomplicated by other major comorbid conditions. Interestingly, we identified fewer trials that were conducted among patients at high risk for CHD, such as those with diabetes or preexisting cardiovascular disease. These patients could benefit the most from improvement in their lipid profiles and are the most likely to be receiving more aggressive lipid-modifying regimens in clinical practice.

Limitations of the Evidence Base and Review Process

The SOE was insufficient for many comparisons and outcomes because of a paucity of studies and poor quality of existing studies. Trials were frequently downgraded in risk-of-bias assessment for lack of blinding by participant and study personnel (performance bias), for not reporting the blinding of outcome assessors (detection bias), or for not accounting for losses to followup or handling of incomplete data (attrition bias). Few studies reported variance estimates for the between-group differences in any outcomes over time. In some instances, the studies did not report a mean difference or point estimate, stating only that there was no significant difference between the groups. In addition, some studies did not report an intention-to-treat analysis and others did not specify the number analyzed in each arm. All of these factors limited our ability to conduct meta-analyses. Where we conducted meta-analyses, substantial heterogeneity was present in most cases.

The evidence base was also limited due to the short duration of most studies. Most trials we identified were of relatively short duration, despite the fact that these medications are currently used in clinical practice as chronic long-term medications. Studies were of insufficient duration to adequately assess long-term clinical outcomes, including mortality, acute coronary events, and revascularization procedures. In addition, losses to followup and medication adherence were often not reported by intervention arm in trials, which may bias our results. While our findings may suggest that one therapeutic option provides a benefit over another, we cannot comment on the tolerability of or persistence with the regimen, given the lack of data and short trial duration. Additional long-term trials are needed to compare the tolerability, side effects, and harms with prolonged use of these combinations.

The review process imposed limitations as well. First, the review focused narrowly on combination therapy
compared with statin intensification. As a result, many studies of add-on combination therapy versus the same statin dose or nonstatin monotherapy were excluded because they did not address the Key Questions. Given several previous reviews on dietary modification and reduction of lipids and CVD risk, we did not include these therapies in this review.\textsuperscript{18,19} Further, we did not examine differences in statin response based on genetic variations.\textsuperscript{20,21} Second, we excluded non–English-language publications, although we do not believe this introduced significant bias. Third, because this review was conducted prior to the release of the 2013 cholesterol treatment guidelines from the American College of Cardiology/ American Heart Association Task Force, we could not define our population eligibility criteria to match their four “statin benefit groups” and our potency categorizations differ slightly from those in the guidelines.\textsuperscript{10}

\textbf{Future Research Needs}

We suggest that most comparisons and outcomes that have low or insufficient evidence are future research needs. In order to answer whether there are long-term benefits with respect to mortality, acute coronary events, and revascularization procedures, future investigators need to make these endpoints the primary outcomes of their trials and ensure that trials are of sufficient duration to actually capture these events (at least 12 months and preferably longer). Short-term trials using surrogate endpoints are of diminishing value at this point. We further suggest that future studies focus on high-risk CHD populations and populations with greater burden of cardiovascular disease to determine which strategy provides better short-term improvements in lipid profile and long-term clinical benefits. These populations include patients with diabetes and preexisting cardiovascular disease, as well as Black and Native American populations.\textsuperscript{22} It may be worthwhile to explore differences between men and women, as the ACCORD trial showed benefit of combination therapy with fibrate in men and potential harms with this combination therapy in women.\textsuperscript{14} Such studies would have tremendous impact on clinical practice, as these patients with greater burden of cardiovascular disease are the most likely to need a more aggressive lipid-modifying regimen.

While head-to-head comparisons of a combination regimen to intensification of statin therapy may answer important clinical questions, these trials do not help clinicians decide between different combination therapy options. Once the effectiveness of each combination regimen on long-term clinical outcomes is established, the next step to inform clinical decisionmaking would be to help clinicians determine how to select the most appropriate lipid-modifying regimen from all available options. We suggest that future studies conduct head-to-head comparisons of multiple combination regimens against each other as well as against intensification of statin monotherapy to address this need. Additionally, it would be useful to examine whether it is possible to achieve LDL-c reductions consistent with those from potent statins (50–60%) in patients who are unable to tolerate full-dose statin therapy and what the clinical effects of these reductions would be. Furthermore, it would be useful to determine if LDL-c lowering of 50 percent achieved with a statin and a bile acid sequestrant is as efficacious as similar LDL-c lowering with a statin and ezetimibe, and whether both used together are as efficacious as a potent statin alone. Finally, alternative study designs, such as observational studies using registry data from electronic medical records, may also provide useful data on clinical outcomes.

\textbf{Conclusions}

Although many studies looked at intermediate outcomes, few studies addressed the question of which approach produces better clinical outcomes. Combination of statin with ezetimibe or bile acid sequestrant lowered LDL-c better than intensification of statin monotherapy, but evidence for clinical outcomes (mortality, acute coronary events, and revascularization procedures) was insufficient across all potency comparisons for all combination therapy regimens. Additional studies evaluating long-term clinical benefits and harms are needed to better inform clinical decisionmaking, patient choice, and clinical practice guidelines.

\textbf{References}


Full Report